Acrivon therapeutics announces inducement grants under nasdaq listing rule 5635(c)(4)

Watertown, mass., jan. 12, 2024 (globe newswire) -- acrivon therapeutics, inc. (“acrivon” or “acrivon therapeutics”) (nasdaq: acrv), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, acrivon predictive precision proteomics or ap3, announced that the company approved a grant of an equity award under its 2023 inducement plan to one employee. the equity award was granted in the form of stock options and has a grant date of january 11, 2024.
ACRV Ratings Summary
ACRV Quant Ranking